Purpose: This study aimed to report the adjuvant radiotherapy results of pediatric patients with Ewing sarcoma who received multimodal treatment for this rare disease using modern radiotherapy (RT) techniques. Materials and Methods: Pediatric patients with Ewing Sarcoma (ES) who received adjuvant radiotherapy were evaluated retrospectively. The study's primary endpoint was Overall Survival (OS) and disease-free survival (DFS). The secondary endpoint was local relapse-free survival after RT (LRFS- RT) and overall survival after RT (OS-RT). Results: The results of 18 pediatric patients diagnosed with Ewing Sarcoma in our clinic between 09.12.2013- 04.04.2021 and underwent RT for adjuvant were evaluated retrospectively. The three patients were excluded since they did not meet the inclusion criteria. The median age of the patients at the time of diagnosis was 10.5 (range 3-17). All the patients received pre-RT chemotherapy according to EURO-EWING 99. All the patients were operated and 7 (46.7 %) patients were R0; 4 (26.7%) patients were R1, and 4 (26.7%) patients were R2. RT was administered to patients for adjuvant purposes. The time from diagnosis to the onset of RT was 8.6 (range 2-20) months. The median fraction dose was 180 cGy, and the median total RT dose was 50.4 (range 45-55.80) Gy. The three patients (20%) received less than a total of 50 Gy, and 12 (80%) patients received a total of 50 Gy or more. The median follow-up period of the study was 27 (range 11-86) months. The 12 (80%) patients survived, and 3 (20%) died. The median OS diagnosis of the patients was 27.3 (range 11 to 86.5) months. The overall survival of the patients after RT was median 17.3 (range 4.4-83.9) months. Recurrence (local + distant) was observed in 7 patients (46.7%); 2 (13.3%) local, 3 (20 %) distant and 2 (13.3%) both. The median DFS was 24 months (range 1-86.5). Median LRFS-RT is 14.2 (range 1-83.9). The relationship between LRFS-RT and age (< 10 vs. over ≥ years old) (p0.050; HR:2.30; %95 CI 0.70-3.17) was significant. Significantly higher LRFS-RT was observed in the older age. No significant relationship was found between OS diagnosis, OSRT, and DFS and the following variables: gender (female vs. male), age at diagnosis (< 10 vs. over ≥ years old), tumor size (
Aim: This paper aims to evaluate the treatment completion status and survival outcomes of patients who were prescribed radiotherapy during intensive care unit (ICU) hospitalization in the radiation oncology clinic. Material and Method: Data on patients who underwent RT between January 1, 2020, and June 30, 2022, in the Radiation Oncology Clinic of Ankara City Hospital were retrospectively evaluated. The primary endpoint of this study is the patient status at the completion of the planned radiotherapy and the secondary endpoint is the overall survival (OS). The data were recorded and analyzed using SPSS version 26 (IBM Corporation, Armonk, NY, USA). Results: The data of 11 patients who were indicated for radiotherapy while hospitalized for intensive care between May 20, 2020, and June 30, 2022, in the Ankara City Hospital Radiation Oncology Clinic were retrospectively analyzed. The median follow-up period from the onset of RT was 4.1 months (range 1–9.8). During this period, nine (81.8%) patients had deceased, and two (18.2%) patients were surviving. The median age of the patients was 55 years (range 3–70); four (36.4%) were female and seven (63.6%) were male. Seven (63.6%) of the patients completed the planned radiotherapy scheme and four (36.4%) did not complete the treatment. There was no significant relationship between the inability to complete the treatment and gender (p=0.194) or primary diagnosis (p=0.545). The median OS value of the patients was 4.1 months (range 1–9.8). In addition, the 1-month survival was 60.6%, and the 6-month survival was 20%. There was no significant relationship between OS and age (p=0.401; correlation coefficient: ‑282) or primary diagnosis (p=0.638). The median OS in women was 5.3 (range 2.7–9.8) months; the median OS in men was 1 month (range 1–5.5; p=0.059). The median OS of those who completed treatment was 4.5 months (range 1–9.8), while that of those who did not complete the treatment was 1.1 months (range 1–4; p=0.037). Conclusion: Approximately 60% of the patients who were hospitalized in the ICU and indicated for RT were able to complete treatment. A significantly higher OS was achieved in patients who completed the RT protocol. Criteria must be developed when determining the indications for radiotherapy of cancer patients hospitalized in intensive care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.